Preventive health provider teams up with Alamar Biosciences on proteomic biomarkers linked to chronic inflammation and neurological health.
Precision medicine provider Human Longevity, Inc. (HLI) has joined forces with Alamar Biosciences in a new partnership that aims to bring cutting-edge proteomic testing into longevity-focused clinical programs. The collaboration will integrate two of Alamar’s ultra-sensitive proteomic panels into HLI’s diagnostic programs, expanding the company’s capacity for early disease detection and health monitoring.
HLI is set to adopt Alamar’s NULISAseq Inflammation Panel 250 and CNS Disease Panel 120, which measure biomarkers linked to chronic inflammation and neurological health, respectively. Chronic inflammation has long been recognized as a driver of aging and age-related disease, while early detection of neurodegenerative processes has been a persistent challenge in preventive medicine. By deploying Alamar’s panels, which are capable of detecting proteins at attomolar levels, HLI aims to enhance its ability to analyze these pathways for the benefit of its clients.
The technology builds on Alamar’s NULISA platform, which combines multiplexed protein profiling with a level of sensitivity that the company claims surpasses existing detection methods. HLI says it will fold these assays into its Executive Health and 100+ Longevity programs later this year. The move reflects a broader strategy to create predictive models of health by layering proteomic data on top of genomics, advanced imaging, and other multi-omics analyses gathered from more than 10,000 clients to date.
“Proteomics is the next frontier in longevity medicine,” said HLI’s executive chairman Dr Wei-Wu He. “By adding high-resolution protein measurements to our existing genomics and imaging platform, we are moving closer to truly predictive and preventive healthcare.”
Founded by genome pioneer J. Craig Venter, HLI has positioned itself at the intersection of diagnostics, artificial intelligence, and personalized medicine. Earlier this year, the company demonstrated its confidence in its approach by offering a commitment to its members: if a client in its Executive Health Program develops late-stage prostate cancer, the company will cover up to $1 million in advanced treatment costs. That pledge has since been extended to pancreatic, ovarian, and lung cancers.
Earlier this month, Alamar partnered with the German Center for Neurodegenerative Diseases to apply its technology in the Rhineland Study, one of the world’s largest population-based efforts to map aging. Researchers will use Alamar’s assays to analyze 23,000 plasma samples, searching for protein biomarkers that could illuminate mechanisms of healthy aging and disease progression.
Reflecting on the company’s opportunity to work with HLI to advance the science of healthy aging, Alamar CEO Dr Yuling Luo, said, “It’s incredibly meaningful that a trailblazer in longevity research has chosen our precision proteomics platform to drive real-world applications that support longer, healthier lives.”
